The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025.
Nichlas Pollier | Bloomberg | Getty Images
Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal.
The trial tested whether semaglutide — the active ingredient in Novo’s blockbuster diabetes and weight loss drugs Ozempic and Wegovy — helped slow progression for Alzheimer’s disease.
While treatment with semaglutide resulted in improvement of Alzheimer’s disease-related biomarkers in two separate trials, this did not translate into a delay of disease progression, Novo said in a statement Monday. The goal had been to slow patient’s cognitive decline by at least 20%.
Analysts had prior to the results called the trials a long shot, whereas Novo itself had referred it as a “lottery ticket.”
Novo stock was down 8.3% to 279 Danish kroner as of 11:50 a.m. GMT (6:50 a.m. ET).
This is breaking news. Please refresh for updates.
